| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
CST626 targets inhibitor of apoptosis proteins (IAPs). It is a pan-IAP degrader that degrades XIAP, cIAP1, and cIAP2 in MM.1S cells, with DC50 values of 0.7 nM, 2.4 nM, and 6.2 nM, respectively. It also shows activity against other IAP family members.
|
|---|---|
| ln Vitro |
Compound 9, or CST626; its DC50 values are 2.4 nM, 6.2 nM, and 0.7 nM, respectively, and they cause the degradation of cIAP1, cIAP2, and XIAP in a dose-dependent manner [1]. The vitality of cancer cells is considerably inhibited by CST626 (0-10 μM; 96 h) [1].
In vitro, CST626 (0-10 microM; 96 h) shows potent inhibition of cancer cell viability in multiple cancer cell lines. In MOLM13 cells, the IC50 value is 2.1 nM; in SUDHL6 cells, the IC50 value is 1.6 nM. It effectively degrades IAP proteins in a concentration-dependent manner. |
| ln Vivo |
In vivo, CST626 induces DNA damage, promotes apoptosis, and leads to tumor regression in orthotopic WA74 patient-derived xenograft (PDX) models of resistant prostate cancer. It demonstrates significant antitumor efficacy in mouse tumor models, though detailed in vivo protocol data is limited.
|
| Enzyme Assay |
CST626 is typically evaluated in non-cellular binding assays to confirm IAP engagement using purified recombinant XIAP, cIAP1, or cIAP2 proteins in a time-resolved FRET (TR-FRET) or AlphaScreen format to measure binding affinity and degradation initiation. For establishing DC50 values, standard degradation assays are performed with protein quantification by western blot.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: MM.1S cells Tested Concentrations: 0.0001, 0.001, 0.01, 0.1 and 1 μM Incubation Duration: 16 h Experimental Results: Revealed DC50 values of 2.4 nM(cIAP1), 6.2 nM(cIAP2), and 0.7 nM(XIAP). Cell Viability Assay[1] Cell Types: SUDHL6, MOLM13, NCI-H929, K562, DB, JJN3, HEL, SUDHL4 and RPMI-8826 cells Tested Concentrations: 0.01, 0.04, 0.1, 0.4, 1, 4 and 10 μM Incubation Duration: 96 h Experimental Results: Inhibited cell viability with IC50s of 0.0016, 0.0021, 0.0085, 0.42, 0.46, 1.14, 1.17, 1.69 and 2.54 μM against SUDHL6, MOLM13, NCI-H929, K562, DB, JJN3, H EL, SUDHL4 and RPMI-8826 cells, respectively. For in vitro cellular assays, cells (e.g., MM.1S, MOLM13, or SUDHL6) are seeded in 96-well plates at optimal density. CST626 (0-10 microM range) is added for 48-96 hours. Cell viability is assessed using a luminescent cell viability assay (e.g., CellTiter-Glo). Western blotting is used to measure degradation of XIAP/cIAP1/cIAP2 with beta-actin as loading control. DC50 and IC50 values are calculated from dose-response curves. |
| Animal Protocol |
For in vivo animal efficacy studies, CST626 is typically administered via intraperitoneal injection (e.g., once daily for 14-21 days) at doses of 5-30 mg/kg in mice bearing orthotopic PDX tumors. Tumor volumes are measured twice weekly using calipers. Body weight is monitored to assess tolerability. At study termination, tumors are excised, weighed, and analyzed for IAP degradation by Western blot.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of CST626 are those typical of a PROTAC molecule with molecular formula C61H82N8O9S (MW 1103.42). The compound is formulated in solvents like DMSO or PEG400 for in vivo administration. It is recommended to store the powder at -20degC for up to 3 years and in solution at -80degC for 6 months.
|
| Toxicity/Toxicokinetics |
In preclinical studies, CST626 shows a favorable safety profile at therapeutic doses. Standard safety pharmacology studies (e.g., hERG, CYP inhibition, and genotoxicity) would be required for clinical development. At high doses, off-target degradation and general cytotoxicity may occur. It is intended for research use only and not for human therapeutic applications.
|
| References | |
| Additional Infomation |
CST626 (CAS: 3033993-13-1) is a pan-IAP PROTAC degrader classified under the PROTACs category. Its mechanism of action involves recruiting an E3 ubiquitin ligase to IAP proteins, leading to their ubiquitination and subsequent proteasomal degradation. It is used in cancer research, particularly for apoptosis studies.
|
| Molecular Formula |
C61H82N8O9S
|
|---|---|
| Molecular Weight |
1103.42
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9063 mL | 4.5314 mL | 9.0627 mL | |
| 5 mM | 0.1813 mL | 0.9063 mL | 1.8125 mL | |
| 10 mM | 0.0906 mL | 0.4531 mL | 0.9063 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
